MINNEAPOLIS, Dec. 10, 2013 /PRNewswire/ -- Uroplasty, Inc. (NASDAQ: UPI) a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions, today announced that David B. Perry has joined the Company as Vice President of Marketing. He joins Uroplasty with nearly 20 years of experience developing, branding and commercializing medical device products resulting in market leadership, share gains and new sales opportunities in global markets.
"Dave's proven ability to develop and execute innovative marketing strategies will be a valuable asset to our growth plans as we work towards both broadening and re-engaging our U.S. Urgent PC customer base of physicians," said Darin Hammers, Senior Vice President of Global Sales and Marketing. "His experience in revitalizing underperforming product lines and success in implementing revenue generating product strategies makes Dave an ideal fit for leveraging the initiatives already underway through our sales organization."
Mr. Perry's experience includes more than 10 years directing domestic and global product marketing initiatives in the endourology, prostate and men's health divisions at American Medical Systems (AMS), an Endo Health Solutions company. Prior to joining AMS, Mr. Perry held key marketing roles at Boston Scientific and Kendall Healthcare (Covidien, Inc.).
Mr. Perry holds a Bachelor of Science degree from Brigham Young University's Marriott School of Management.
About Overactive Bladder
Overactive bladder (OAB) is a chronic condition that affects approximately 34 million US adults. The symptoms include urinary urgency, frequency and urge incontinence. The Urgent PC Neuromodulation System is the only FDA cleared device that delivers Percutaneous Tibial Nerve Stimulation (PTNS) therapy.
About Uroplasty, Inc.
Uroplasty, Inc., headquartered in Minnetonka, Minnesota, with wholly-owned subsidiaries in The Netherlands and the United Kingdom is a global medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions. Our focus is the continued commercialization of our Urgent® PC Neuromodulation System, the only FDA-cleared system that delivers percutaneous tibial nerve stimulation (PTNS) for the office-based treatment of overactive bladder and associated symptoms of urgency, frequency and urge incontinence. We also offer Macroplastique®, an injectable urethral bulking agent for the treatment of adult female stress urinary incontinence primarily due to intrinsic sphincter deficiency. For more information on the company and its products, please visit Uroplasty, Inc. at www.uroplasty.com.
For Further Information:
Brett Reynolds, SVP and CFO
Leigh Salvo (Investors)/Janine McCargo (Business Media)
|SOURCE Uroplasty, Inc.|
Copyright©2012 PR Newswire.
All rights reserved